Trial Information

Summary: PHI-54 NCI #7540: Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

You are being asked to take part in this study because you have been diagnosed with a malignant solid tumor that is either resistant to standard drugs or has relapsed and alternative therapies (such as surgery and/or radiation therapy) will not cure the cancer. The purpose of this study is to find the highest dose of intravenous (IV, into a vein) fenretinide can be given to subjects with malignant solid tumors without causing unmanageable side effects. Another purpose is to evaluate side effects and to collect information on effectiveness of the treatment. Another purpose is to study the levels of this combination of drugs that remain in the body over time .Your participation in this study is expected to last for as long as your tumor is not growing and you are not having any unmanageable side effects for up to 6 treatment cycles (21 days each). If you have responded to the treatment favorably, you may be eligible to continue receiving further treatment once you have finished the study treatment of 6 cycles, if you desire, provided the drug is available. After you complete treatment on this study, your condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 3:00:53 PM